Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

Anas Younes, MD
Published Online: Tuesday, May 6, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

In a session at the 18th Annual International Congress on Hematologic Malignancies®, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.

There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.

Online CME Activities
Free CME from PER
Cardiology Review/CME Reviews: Volume 31, Number 2
Community Practice Connections: 19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
Addressing Disparities in Care Specific to Patients With Lung Cancer: Health Literacy
Addressing Disparities in Care Specific to Patients With Lung Cancer: Patient Cases
More Reading
$auto_registration$